Patient
SITE015-0198
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE015 (POL) (Dr. Ito)
consented 2026-04-21
Adverse events
5
Serious AEs
0
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 5
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-03-05 (study day 123); relationship: not assessed
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-03-02 (study day 120); relationship: NOT RELATED
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-09 (study day 68); relationship: NOT RELATED
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-28 (study day 56); relationship: NOT RELATED
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-11-30 (study day 28); relationship: RELATED
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.